A Phase 1 Dose Escalation Trial of Ipilimumab in Combination With CG1940 and CG8711 in Patients With Metastatic Hormone-Refractory Prostate Cancer.

Trial Profile

A Phase 1 Dose Escalation Trial of Ipilimumab in Combination With CG1940 and CG8711 in Patients With Metastatic Hormone-Refractory Prostate Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2012

At a glance

  • Drugs Ipilimumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Mar 2012 Results were published in The Lancet Oncology (February 2012) journal, according to a BioSante Pharmaceuticals media release
    • 19 Jan 2012 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top